My Authors
Read all threads
#Migraine patients were excluded from Eli Lilly's trial of #Emgality 300 in which 71.4% of people got +50% reduction in #headache days. Only 28% of people taking 120 mg hit this benchmark. Trial exclusion means FDA did NOT approve 2.5x more effective 300 for CM. @LillyPad thread
Trial exclusions determine FDA "labeled" usage. Insurers routinely cover off-label use of inexpensive meds & deny off-label use of expensive meds. Eli Lilly priced #Emgality high: $6,900/year. investor.lilly.com/news-releases/…
Both #cluster & #migraine are profoundly disabling diseases w/ overlapping symptoms. #Emgality treats both. People fully disabled by 1 are no more/less disabled than people fully disabled by the other, so why did Lilly assume #cluster required nearly 3x more med?
#Cluster affects 9x more men than women. Cluster patients have a special status among doctors. In "Conquering Headache" (2003), 3 prominent male neurologists describe cluster as "so excruciating that it brings even the strongest of men to their knees" (p 13).
.@WHO ranks severe #migraine in highest class of disease burden, along w/ terminal-stage cancer, quadriplegia, & active psychosis. Yet migraine (which affects 3x as many women as men) is undertreated. Lilly's #Emgality trial design is as shameful an example of this as any.
Inexplicably, Eli Lilly failed to consider its own shareholders when deciding to include only #cluster patients in its trial of #Emgality 300 trial. There are 40 times as many Americans w/ chronic #migraine as there are people w/ #cluster. @LillyPad
.@headsUPmigraine has heard from both neurologists & patients that #Emgality 300 mg can, indeed, have superior results compared to 120 mg for people w/ limited response to the lower dose. This is life-changing for patients fully disabled by intractable, continuous #migraine.
2/2019, Eli Lilly announced that full-year 2018 revenue increased 7% to $24.556 billion. “The company now anticipates 2019 revenue between $25.1 billion & $25.6 billion. … Revenue growth is also expected to benefit from the recent launch of #Emgality.” investor.lilly.com/news-releases/…
.@headsUPmigraine calls on Eli Lilly to fund & submit to FDA a small trial of #Emgality 300 for chronic #migraine so patients can receive insurance coverage for its $1,600/year med. @LillyPad
headsUP urges Eli Lilly to immediately open its 1-year trial of #Emgality 300 mg to those intractable #migraine sufferers identified by doctors as likely to benefit from the higher, more effective 300 mg dose. @LillyPad docs.google.com/document/d/e/2…
Missing some Tweet in this thread? You can try to force a refresh.

Enjoying this thread?

Keep Current with Jill Piggott

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!